NCT03429218View on ClinicalTrials.gov

First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

March 8, 2021

Study Completion Date

March 8, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

TP-0184

Oral dose once weekly for 4 weeks

Trial Locations (5)

30342

Northside Hospital, Atlanta

66160

University of Kansas Medical Center Research Institute, Kansas City

85258

Honor Health, Scottsdale

02215

Massachusetts General Hospital MGH, Boston

75390-9179

University of Texas Southwestern UTSW, Dallas

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03429218 - First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter